Compare Kinder Morgan Inc (KMI) vs State Street SPDR S&P Biotech ETF (XBI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Kinder Morgan Inc vs State Street SPDR S&P Biotech ETF — how do they compare? Kinder Morgan Inc trades at $31.75 (market cap $70.10B), while State Street SPDR S&P Biotech ETF trades at $158.9. The key difference: Kinder Morgan Inc pays a 3.75% dividend while State Street SPDR S&P Biotech ETF pays none, and State Street SPDR S&P Biotech ETF is trading nearer its 52-week high, Kinder Morgan Inc nearer its low. Which is the better fit depends on your goals.
| KMI | XBI | |
|---|---|---|
Market Cap | $70.10B | — |
Sector | Energy | Broad Market / Factor |
52-Week High | $34.31 | $164.28 |
52-Week Low | $25.84 | $86.92 |
Enterprise Value | $102.15B | — |
Dividend Yield | 3.75% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
KMI trades at $31.76, up 1.16% today, with a bearish technical signal from moving averages but neutral oscillators. The company reported strong Q2 2026 earnings, beating estimates, and raised full-year guidance. Revenue grew to $16.94B in 2025, with net income margin expanding to 19.31%. Recent news highlights a $5 billion Western Gateway Pipeline joint venture final investment decision.
Outlook is supported by robust cash flow, a $10 billion project backlog, and growing LNG demand, but risks include high debt levels and execution challenges. Analysts are mixed with 47% buy ratings. The stock offers a dividend yield near 3.7%, appealing for income-focused investors amid stable fee-based operations.
XBI trades at $158.81, up 0.49% today, with a bullish technical signal supported by moving averages. The ETF shows strong momentum with a 17% monthly gain and 75% annual return, driven by biotech sector strength. Analyst coverage is limited to one hold rating, while recent news highlights institutional buying interest and positive sector developments including M&A activity and drug trial successes.
The outlook remains positive given biotech's breakout from multi-year bear markets, though elevated volatility and policy risks persist. Key opportunities include AI-driven drug discovery and sustained M&A momentum, while risks involve sector-specific volatility and regulatory uncertainty. The ETF's equal-weight approach provides diversified exposure to biotech innovation.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Kinder Morgan Inc
Kinder Morgan is one of the largest midstream energy firms in North America, with an interest in or an operator on about 83,000 miles in pipelines and over 140 storage terminals. The company is active in the transportation, storage, and processing of natural gas, crude oil, refined products, natural gas liquids, and carbon dioxide. The majority of Kinder Morgan's cash flows stem from fee-based contracts for handling, moving, and storing fossil fuel products.
Read more on KMI →About State Street SPDR S&P Biotech ETF
XBI is an equal-weighted ETF that tracks the U.S. biotechnology segment. It provides diversified exposure to small, mid, and large-cap biotech firms involved in drug discovery and medical research, such as Moderna and Exact Sciences.
Read more on XBI →
